Coverage / ZYME / Trade Card

ZYME

Zymeworks Inc

OPPORTUNISTIC BUY 2026-08-01 Updated today USD 21.94 Healthcare - BiotechnologyAWAIT ENTRY
59

Position levels

Currenttoday
USD 21.94
Buy <=wait / entry
USD 17.83
Trim >=take some off
USD 27.50
Thesis breakA negative pivotal-stage readout for zanidatamab or a confirmed failure of the T...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case26%100 / 10026.0
Base case49%62 / 10030.4
Bear case25%10 / 1002.5
Weighted conviction59 / 100 - OPPORTUNISTIC BUY

Top risks

  • Proposed acquisition of Theravance Biopharma
  • Strategic partnerships with Jazz, BeOne and J&J for zanidatamab development and commercialization
  • Q1 2026 EPS miss of -$0.59 vs. -$0.10 estimate
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.